Catalog
GIP / GLP-1 / Glucagon triple agonist

Retatrutide

Triagonist showing ~24% weight loss at 48 weeks in phase 2 — phase 3 ongoing.

InvestigationalGrade B — Supported, context-specific
Target
GIPR + GLP-1R + GCGR

Mechanism of action

Adds glucagon receptor agonism (energy expenditure, hepatic lipid mobilization) to dual incretin scaffold. Mechanistic risk: hyperglycemia mitigation depends on dominant incretin arm.

Pharmacokinetics

SC weekly.

Clinical context

Investigational for obesity, T2D, MASH.

Safety

Contraindications
  • Investigational — see protocol
Adverse effects
  • GI (dose-limiting)
  • Heart-rate elevation
  • Theoretical hepatic glucose output increase

Relevant labs

Hemoglobin A1cALT / AST

Covered in modules

Module 04
Tirzepatide & Multi-Agonists
Dual GIP/GLP-1, GLP-1/glucagon, and triple agonists — beyond Ozempic.
Module 15
Controversies, Pipeline & Frontier
What's in phase II/III right now — and what 2027 will probably look like.

Key references

Related compounds

Dual GIP / GLP-1 receptor agonist
Tirzepatide
Synthetic tuftsin analog (anxiolytic peptide)
Selank
Synthetic ACTH(4–10) analog
Semax
Khavinson 'bioregulator' tetrapeptide (Ala-Glu-Asp-Gly)
Epitalon (Epithalon)

Generate prescriber-grade deep dive

Pull in expanded mechanism, PK/PD, dosing strategies for special populations, drug interactions, monitoring cadence, head-to-head differentials, prescriber pearls, and patient FAQs for Retatrutide.

Educational reference. Not medical advice. Always verify against current FDA labeling and local regulatory guidance before prescribing or counseling.